Hosted on MSN14d
Candel initiated at buy by Citi, lead immunotherapy drugs cited
BofA believes Candel (NASDAQ:CADL) could have peak sales of $2.9B by 2029. It noted that its cash runway of $103M should be able to take it into Q1 2027, which would support not only this year's ...
Hosted on MSN1d
Citigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
Fintel reports that on February 20, 2025, Citigroup initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy recommendation. Analyst Price Forecast Suggests 65.62% Upside As of February 19 ...
Nasdaq24d
B of A Securities Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation
Fintel reports that on February 7, 2025, B of A Securities initiated coverage of Candel Therapeutics (NasdaqGM:CADL) with a Buy recommendation. As of January 29, 2025, the average one-year price ...